192 related articles for article (PubMed ID: 32448607)
41. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
[TBL] [Abstract][Full Text] [Related]
42. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.
Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS
Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785
[TBL] [Abstract][Full Text] [Related]
43. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
45. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
[TBL] [Abstract][Full Text] [Related]
47. The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer.
Cai C; Zhu X
Mol Med Rep; 2012 May; 5(5):1191-6. PubMed ID: 22367735
[TBL] [Abstract][Full Text] [Related]
48. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
49. miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway.
Zhang W; Shen C; Li C; Yang G; Liu H; Chen X; Zhu D; Zou H; Zhen Y; Zhang D; Zhao S
Mol Carcinog; 2016 May; 55(5):575-85. PubMed ID: 25764520
[TBL] [Abstract][Full Text] [Related]
50. MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133
Yang L; Li N; Yan Z; Li C; Zhao Z
J Mol Neurosci; 2018 Nov; 66(3):369-377. PubMed ID: 30267383
[TBL] [Abstract][Full Text] [Related]
51. Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma.
Khan M; Muzumdar D; Shiras A
Neoplasia; 2019 Jan; 21(1):106-116. PubMed ID: 30530053
[TBL] [Abstract][Full Text] [Related]
52. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).
Jin J; Grigore F; Chen CC; Li M
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013362
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein.
Li D; Wang Z; Chen Z; Lin L; Wang Y; Sailike D; Luo K; Du G; Xiang X; Jiafu GD
Biochem Biophys Res Commun; 2016 Dec; 481(3-4):245-250. PubMed ID: 27815074
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.
Kahlert UD; Suwala AK; Koch K; Natsumeda M; Orr BA; Hayashi M; Maciaczyk J; Eberhart CG
J Neuropathol Exp Neurol; 2015 Sep; 74(9):889-900. PubMed ID: 26222502
[TBL] [Abstract][Full Text] [Related]
55. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
[TBL] [Abstract][Full Text] [Related]
56. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
57. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
58. Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.
Pavon LF; Sibov TT; de Oliveira DM; Marti LC; Cabral FR; de Souza JG; Boufleur P; Malheiros SM; de Paiva Neto MA; da Cruz EF; Chudzinski-Tavassi AM; Cavalheiro S
Oncotarget; 2016 Jun; 7(26):40546-40557. PubMed ID: 27244897
[TBL] [Abstract][Full Text] [Related]
59. CD133: beyond a cancer stem cell biomarker.
Barzegar Behrooz A; Syahir A; Ahmad S
J Drug Target; 2019 Mar; 27(3):257-269. PubMed ID: 29911902
[TBL] [Abstract][Full Text] [Related]
60. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells.
Nakata S; Campos B; Bageritz J; Bermejo JL; Becker N; Engel F; Acker T; Momma S; Herold-Mende C; Lichter P; Radlwimmer B; Goidts V
Brain Pathol; 2013 Jan; 23(1):60-72. PubMed ID: 22805276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
